BioSpace News Archive

Willow Biosciences Inc. (“Willow”) (TSX: WLLW) (OTCQB: CANSF) today released its financial and operating results for the three months ended June 30, 2023, reporting further progress in its commercial expansion.

Mirati Therapeutics, Inc., a commercial stage biotechnology company, announced that it intends to offer and sell $250.0 million of shares of its common stock, and, to certain investors, pre-funded warrants to purchase shares of common stock, in an underwritten public offering.

Invitae, a leading medical genetics company, announced financial and operating results for the second quarter ended June 30, 2023.

BioLife Solutions, Inc. announced financial results for the second quarter and six months of 2023 and updated guidance for the full year 2023.

Regulus Therapeutics Inc. (Nasdaq: RGLS), a biopharmaceutical company focused on the discovery and development of innovative medicines targeting microRNAs (the “Company” or “Regulus”), today reported financial results and provided a corporate update for the second quarter ended June 30, 2023.

Gossamer Bio, Inc. (Nasdaq: GOSS) today announced its financial results for the second quarter ended June 30, 2023, and provided a business update.

Atara Biotherapeutics, Inc. (Nasdaq: ATRA), a leader in T-cell immunotherapy, leveraging its novel allogeneic Epstein-Barr virus (EBV) T-cell platform to develop transformative therapies for patients with cancer and autoimmune diseases, today reported financial results for the second quarter 2023, recent business highlights and key upcoming catalysts.

KORU Medical Systems (NASDAQ: KRMD) (“KORU Medical” or the “Company”) today announced that the Company will participate in the Canaccord Genuity 43rd Annual Growth Conference on August 10, 2023.

Verastem Oncology (Nasdaq: VSTM), a biopharmaceutical company committed to advancing new medicines for patients with cancer, today reported financial results for the second quarter ending June 30, 2023 and highlighted recent progress.

Vapotherm, Inc. (NYSE: VAPO), (“Vapotherm” or the “Company”), today announced second quarter 2023 financial results.